Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK

Current Medical Research and Opinion

Volumn 21, Issue 5, 2005, Pages 805-815

  Guest, Julian F ^a   Clegg, John P ^a   Davie, Alison M ^a   McCloskey, Eugene ^b  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonate; Breast cancer; Costs; Pamidronate; UK; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; PAMIDRONIC ACID; SEX HORMONE; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG INDICATION; DRUG INFUSION; ECONOMIC ASPECT; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; LABORATORY TEST; MODEL; RESOURCE MANAGEMENT; REVIEW; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCIUM METABOLISM DISORDERS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIPHOSPHONATES; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; IMIDAZOLES; MIDDLE AGED; STATE MEDICINE;

EID: 18844440666     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X40472     Document Type: Review

References (19)

1. Souhami R, Tobias J, editors. Breast cancer. In: Cancer and its management. Oxford: Blackwell Science; 1998. pp. 216-34
2. Paterson AHS. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer 2000;88:3038-46
3. The Breast Specialty Group of the British Association of Surgical Oncology. British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. Eur J Surg Oncol 1999;25:3-23
4. Lacerna L, Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumours. Seminars in Oncology 2003;30(5 Suppl 16): 150-60
5. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. The Cancer Journal 2001;7(5):377-87
6. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technology Assessment 2004;8(4)
7. Pavlakis N, Stockier M. Bisphosphonates for breast cancer (Cochrane review). The Cochrane Library, vol. 4. Chichester, UK: John Wiley & Sons, Ltd; 2003
8. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [Myeloma Aredia Study Group]. NEJM 1996;334(8):488-93
9. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [Myeloma Aredia Study Group]. J Clin Oncol 1998;16(2):593-602
10. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate [Protocol 19 Aredia Breast Cancer Study Group]. J Clin Oncol 1998;16(6):2038-44
11. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases [Protocol 19 Aredia Breast Cancer Study Group]. NEJM 1996;335(24):1785-91
12. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is an effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082-90
13. NHS Executive Reference Costs 2003. Leeds: Department of Health 2003
14. BNF (British National Formulary). London: BMA and Royal Pharmaceutical Society of Great Britain, 2004
15. Datamonitor. Treatment algorithms 2001: Breast cancer. Reference Code: DMHC1683. 2001. Datamonitor, London
16. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia; WB Saunders Co.; 1980. pp. 228-65
17. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98(8):1735-43
18. Romanus D, Iscoe N, DeAngelis C, et al. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Supportive Care in Cancer 2004 [published on line]
19. DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care in Cancer 2001;9:545-51